🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526359-75-00
Authorised Phase IV

A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013

2026-526359-75-00 · tracked via the Priya Life Science EU tracker
Sponsor
Urogen Pharma Ltd.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
11/09/2026
Enrollment target
13
Sites
Latvia

Condition studied

Non-Muscle Invasive Bladder Cancer

Investigational medicinal product(s)

UGN-103 (Mitomycin)

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Duration of response (DOR)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526359-75-00 on CTIS ↗ ← All trials in the EU